A novel, highly selective RNase inhibitor, B-I09, mimicked XBP1 deficiency in CLL cells by upregulating IRE1a expression level and compromising BCR signaling. This evidence concerns the gene XBP1 and B-cell chronic lymphocytic leukemia.